Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. [electronic resource]
Producer: 19970603Description: 3323-9 p. digitalISSN:- 0006-4971
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- biosynthesis
- Age Factors
- Aged
- Aged, 80 and over
- Antigens, CD -- biosynthesis
- Antigens, CD34 -- biosynthesis
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Chromosome Aberrations
- Chromosome Disorders
- Cytarabine -- administration & dosage
- Daunorubicin -- administration & dosage
- Double-Blind Method
- Drug Resistance, Multiple -- genetics
- Female
- Granulocyte Colony-Stimulating Factor -- therapeutic use
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Leukemia, Promyelocytic, Acute -- drug therapy
- Male
- Middle Aged
- Neoplasms, Second Primary -- drug therapy
- Recombinant Proteins -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.